



No. SO (PM&I) 2-1/2020-21/CPC(CRC)  
**GOVERNMENT OF SINDH**  
**HEALTH DEPARTMENT**  
(PROCUREMENT MONITORING & INSPECTION)  
Karachi, Dated, the 4<sup>th</sup> February, 2021

✓  
The Managing Director,  
Sindh Public Procurement Regulatory Authority,  
Karachi.

**Sub: NIT REF: NO. 1813/2020 DATED: 19-07-2020 APPROVAL OF PROCUREMENT OF DRUGS / MEDICINES / SURGICAL SUNDRIES, DISPOSABLE ITEMS / SURGICAL SUTURE / DENTAL MATERIAL ITEMS UNDER CENTRALISED RATE CONTRACT 2020-21.**

I am directed to enclose herewith copy of minutes of the meetings of Complaint Redressal Committee (CRC) for Tender No. 01 (Group: A,B,C,D,E,F & G) held on 11<sup>th</sup> 12<sup>th</sup> & 13<sup>th</sup> January, 2021 under the Chairmanship of Secretary Health Sindh for further necessary action and hoisting on Authority's website, accordingly.

*Muhammad Yameen*  
(MUHAMMAD YAMEEN)  
SECTION OFFICER (PM&I)

C.C to:

- 1) The Chairman & All members of Central Procurement Committee (CPC), Health Department.
- 2) The Complainants (All) M/s. \_\_\_\_\_ along-with a copy of minutes of the meeting of CRC for information.
- 3) The P.S. to Minister Health Sindh.
- 4) The P.S to Secretary Health, Govt. of Sindh Karachi.

SECTION OFFICER (PM&I)

*Please  
Host on Authority  
Website.*  
*AD (R)*

SPPRA INWARD DIARY  
NO : 2124  
DATED : 8/2/21

*8/2/21*

**MINUTES OF THE MEETING OF**  
**COMPLAINT REDRESSAL COMMITTEE (CRC)**  
**FOR TENDER NO.01 (GROUP = A,B,C,D,E,F & G)**  
**HELD ON: 11<sup>TH</sup> 12<sup>TH</sup> & 13<sup>TH</sup> JANUARY, 2021**

A meeting of Complaint Redressal Committee was held on 11<sup>th</sup> 12<sup>th</sup> & 13<sup>th</sup> January 2021 under the Chairmanship of Secretary Health, Govt. of Sindh, in view of various complaints received from aggrieved bidder against technical/financial evaluation finalized by the Central Procurement Committee (CPC) [Technical Evaluation Committee (TEC) & Technical sub-committee] invited by Health Department under Centralized Rate Contract System for the year 2020-21. Following members of the committee attended the meeting:

1. **Dr. Kazim Hussain Jatoi**  
Secretary to Government of Sindh, Health Department.
2. **Professor Dr. Azra Saleem,**  
Professor of Pharmacology, SMBBMC Lyari, Karachi.
3. **Dr. Sikander Qureshi**  
Head and Dean Medicine & Allied, SMBBMC Lyari, Karachi.
4. **Dr. Ali Sheer Khakheli**  
Asstt. Professor of Surgery, SMBBMC Lyari, Karachi.
5. Representative of Accountant General Sindh, Karachi not attended the meeting.
6. **Mr. Abdul Hafeez Shar,** Senior Pharmacist, Liaquat University Hospital, Hyderabad has attended the meeting as Co-opt. Technical member.

All representatives of complainants attended the meeting. The representative of respective firms explained their complaints / grievances in detail before the Committee while the experts committee of CPC for evaluation produced relevant record for verification. The Committee examined and discussed the complaints thoroughly and after verification of relevant record and discussion, deliberation on each point and examination of all record, the Committee unanimously decided as under:

S.#	Name of Complainant's and details of Complaint.	CRC Findings / Decisions
01.	<p><b><u>VISION PAHRMACEUITCALS</u></b>  <b><u>MIV -0012,</u></b>            0013,0014,0018,0019,0045,0046,0032,0034 &amp; 0035            They have submitted their grievances for tender No.01 (D) IV Fluids / Infusion which are as under:            They were technically qualified responsive bidder and rates are declared lowest but due to "combined scoring method", M/s. FDL emerged as successful bidders. Combined scoring system is using for consultancy / services. They have referred the objections of the review committee of SPPRA declared "mis-procurement" during 2018-19. They have provided the comparison of rates with successful bidders and reported to direct Chairman CPC to address the issue on priority basis and omit clause of combined scoring from the bidding documents and award the contract to technically qualified and financially lowest evaluated / responsive bidder as per SPPRA Rule.</p>	<p>The CRC observed that the tenders were invited by the CPC on QCBS method as allowed by the Sindh Cabinets in the year 2018-2019 and allowed for such amendments in rules in its meeting held on 22.07.2019. In view of Cabinet decision CRC unanimously rejected the grievances and uphold the decision of CPC.</p>




S.#	Name of Complainant's and details of Complaint.	CRC Findings / Decisions
2.	<p><b><u>JAWED TRADERS</u></b>  <b>MGM-B 0634 &amp; 0537.</b>  They have submitted grievances on above two items, as under:</p> <ol style="list-style-type: none"> <li>1. Tender No. 01 (Group-B) MGM0537, TAB. MEFNAMIC ACID 500mg  They stated that they have quoted original product i.e. Ponstan Forte 500mg manufactured by M/s. Pfizer Rs. 2010/- each and secured 87.62 marks, while you have approved product of <b>M/s. Stanley company</b> (Tab. Kamic Forte) @ Rs. 2.06 with difference of only 1.34 marks. They have requested to consider their branded product.</li> <li>2. Tender No.01 (Group F) MGM0634, INJ. PACLITARES 30mg  They have quoted product of one of largest Mfr. <b>M/s. Pfizer Pakistan</b> at very much discounted rate i.e. <b>Rs. 1070/-</b> per injection but CPC approved the product of <b>M/s. Hilex Pharma</b> (local company) @ Rs. 1500/- each they requested to consider their quoted economical product.</li> </ol>	<p>In view of the review of record of CPC, the CRC rejected the complaint and decided to uphold the decision of CPC.</p>
3.	<p><b><u>SHADANI ENTERPRISES</u></b>  <b>MGM 0634, 0537 &amp; 0577</b>  They stated that they have quoted above item @ very lowest rate i.e. Rs. 4.00 per each and provided all documents including "good storage practice" documents but 04 number of such documents are missing they submitted the comparison as under:  Drop Moxifloxacin.  As per comparative statement:  <b>Shaigan</b> quoted @ Rs. 41.00 marks = 86.00  <b>Bosch</b> quoted @ Rs. 52.00 marks = 88.92  If missing 4 marks may include, the total marks of Shaigan will be 90, and product will be awarded to them at lowest rate and better quality.  They requested to re-evaluate and correct the same.</p>	<p>In view of the review of record of CPC, the CRC rejected the complaint and decided to uphold the decision of CPC.</p>
4	<p><b><u>HIMMEL PHARMACEUTICALS</u></b>  <b>MGM 0250, 0251, 0629, 0634, 0941 &amp; 0942, 0939, 0136, 0137, 0173, 0262, 0263, 0314, 0457, 0458, 0501, 0859, 0919 AND MDP-A 0116 &amp; 011.</b>  They objected that they have participated in tender and quoted anti-cancer portfolio imported from European source and submitted all required documents but unfortunately marks against below certificate / documents , have not been awarded.  For Onko turkey pharmadia Germany &amp; aqvida Germany:  Availability of minimum 25% inventory of total import (letter attached in file but given "0" marks instead of 5).  Valid accreditation of manufacturing unit, attached EUGMP plus all brands API, but given 0 marks instead of 3.  HVAC system stability chamber EGMP of manufacturer + warehouse inspection report attached in file but given 0 marks instead of 4 marks.</p>	<p>Tender documents checked and found that online tender form has been wrongly filled owing to human error but the complaint company deals in high quality medicine, all required documents available on importer file, hence CPC may consider in light of quality based.</p>

*Aga. [Signature]*





S.#	Name of Complainant's and details of Complaint.	CRC Findings / Decisions
5.	<p><b>IMPERIAL TRADERS</b></p> <p><b>MDP-A</b> 0083, 0085, 0086, 0130, 0006, 0010, 0048, 00145, 0146, 0007, 0005, 0095, 0093, 0084, 0079, 0082, 0047, 0049, 0071, 0074, 0119, 0060, 0061, 0059, 0054, 0055, 0052, 0010, 0006, 0050, 0021, 0007, 0005, 0047, 0150, 0132, 0080, 0053, 0055, 0054, 0059, 0061, 0060, 0108, 0147, 0028, 9984, 0030, 0083, 0147, 0085, 0086, 0130, 0028, 0030, 0147, 0028, 0027, 0080, 0083, 0130, 0131, 0132, 0153, 0147, 0148, 0051, 0085, 0086, 0103,</p> <p><b>MGM-B</b> 0230, 0220, 0622, 0623, 0096, 0150, 0081, 0232, 0364, 0595, 0362, 0554, 0510, 0511, 0584, 0256, 0248, 0395, 0596, 0595, 09080191, 0680, 0622, 0300, 0301, 0225, 0376, 0631, 0595, 0095, 0191, 0560, 0232, 0081, 0221, 0243, 0554, 0791, 0528, 0561, 0419, 0536, 0555, 0922, 0765, 0157, 1060, 0220, 0230, 0535, 0537, 0317, 0527, 0108, 0763, 0331, 0330, 0148, 0795, 0330, 0301, 0873, 0756, 0754, 0755, 0786, 0785, 0678, 0679, 0573, 0622, 0623, 0253, 0626, 0540, 0504, 0816, 0300, 0301, 0419, 0918, 0622, 0623, 0639, 0488, 0489, 0520, 0356, 0573, 0575, 0501, 0325, 0461, 0773, 0329, 0578, 0579, 0121, 0327, 0388M 0122, 0351, 0317, 00829, 0899, 0300, 0301, 0662, 0228, 0225, 0573, 0862, 0148, 0901, 0622, 0623, 0230, 0461, 0568, 0788, 0786, 0785, 0056, 0054, 0756, 0754, 0755, 0383, 0385, 0109, 0107, 0382, 0384, 0525, 0679, 0461, 0439, 0323, 0862, 0662, 0062, 0244, 0243, 0245, 0046, 0622, 0623, 0153, 0006, 0626, 0264, 0300, 0301, 0918, 0559, 0560, 0561, 0691, 0039, 0528, 0579, 0579, 0922, 0158, 0419, 0791, 0009, 0325, 0559, 0239, 0670, <b>MIV-D</b> 0019, 0017, 0035, 0046,</p> <p>Objection for invitation of tender on QCBS method for the procurement of drugs / medicines 2020 - 21 dt: 01-12-2020.</p> <p>They have raised objection noted in technical evaluation (manufacturer-wise) which are as under:</p> <p><b>M/s. Amros Pharma:</b></p> <p>They have pointed out quoted items and discrepancies observed generally in all items as under:</p> <p>Factory Score: Documents related to adequate availability of qualified and human resources attached in manufacturer, so 4 marks should be added in factory score.</p> <p>CPC not give 3 marks for binding of files although file is bind.</p> <p>Product Score: Five marks of APIGB were not given although all GDs were attached in manuf. file.</p> <p>CPC not give 5 or 7 marks of API source accreditation.</p> <p>They have pointed out that there have been so much errors found on API source accreditation, immediate container and IMS ranking, which need to be discussed on a large scale. On the basis of above mentioned findings they observed that all products are seen to be selected not evaluated.</p> <p>1. <b>M/s. Imperial Traders</b> have submitted almost same reservation for following manufacturers quoted products also:</p> <p>2. <b>M/s. Elite Pharma.</b></p> <p>3. <b>M/s. ISIS</b></p> <p>4. <b>M/s. Reign Pharma</b></p> <p>5. <b>M/s. Zantoch Pharma</b></p>	<p>All original documents from bid were duly checked and found that no paging available hence, no marks given.</p> <p>Marks of ISOs &amp; GD were also given fairly according to documents provided for all Pharmaceuticals manufacturers pointed out in complaint except following:</p> <p>For M/s. Searle IV infusions:</p> <ul style="list-style-type: none"> <li>- Five (05) items of group-B for ISO marking 03 marks should be awarded which is missing.</li> <li>- Four items of Group-A calibration marks of 04 should be awarded which is missing</li> </ul> <p>For M/s. Elite Pharma:</p> <p>Documents of GSP, function stability chamber and HVAC System were found attached but not attested by FID, so opinion from DRAP to seek to finalise the complainant expert opinion needed.</p>




S.#	Name of Complainant's and details of Complaint.	CRC Findings / Decisions
	<p>3. They have also submitted same reservations including marks of ISO certificate, attached by them and also provided web link on that certificate but CPC not given marks for ISOs :</p> <ol style="list-style-type: none"> <li>1. M/s. Next Pharma</li> <li>2. M/s. The Searle Co.</li> <li>3. M/s. Searle I.V. Infusion.</li> <li>4. M/S. IMPERIAL Traders also pointed out that they have quoted the products of M/s. Saffron Pharma, assigned two distributors for different products i.e. M/s. Imperial Traders and M/s. Shadani Enterprises. On mandatory documents i.e. DML, M/s. Shadani declared "Responsive" whereas, they were declared "Non-responsive" due to non-availability of DML. M/s. Imperial Traders also submitted reservation for invitation of tenders as QCBS method and point out discrepancy in scoring methodology for consideration.</li> </ol>	
6	<p><b>RTJ ENTERPRISES</b>  <b>MGM-B</b> 0039,0792, 0180, 0871, 0300, 0301, 0439, 0821,0861, 0860, 0317, 0676, 0520, 0637, 0214, 0924, 0107, 0109, 0129, 0592, 0862, 0816, 0915, 0899, 0862, 0464, 0785, 0058, 0055,  <b>MGM-A</b> 0129, 0477,  <b>MDP-A</b> 0010, 0089, 0091, 0093, 0005, 0007, 0006, 0310, 0010,0056, 0058, 0083, 0119, 0108, 0174, 0175, 0138, 0140,  <b>MGM-F</b> 0919, 0644, 0645, 0082, 0079, 0121,  <b>MDP-B</b> 0095,  <b>MGM-G</b> 0021, 0022, 0169, 0153,  <b>MGM-E</b> 0208,  They have raised objection noted in technical evaluation (manufacturer-wise) which are as under:</p> <ol style="list-style-type: none"> <li>1. <b>M/s. Reckitt Pharma</b>  They have objected the CPC not given 3 marks of binding despite the file is bind.  IMS point awarded to their competitors are radicules as both products are world re-knownned but unjustified marks to the competitors and not give justified marks of IMS ranking to their both products.  CPC gave 7 marks of API source accreditation to the competitors to win products but all known that API of Paracetamole is locally manufactured.  At the same, errors have been found on API source accreditation immediate container and IMS ranking which need to be discussed on a large scale.</li> <li>2. <b>M/S. Mactor Pharma.</b></li> <li>3. <b>M/s. ICI Pharma</b></li> <li>4. <b>M/s. Geofman Pharma</b></li> <li>5. <b>M/s. Genone Pharma</b></li> <li>6. <b>M/s. Genix Pharma</b></li> </ol> <p>They have raised same observation for evaluation of above said manufacturer as under:  CPC did not give <b>3 marks</b> of binding of files although file is bind.  <b>IMS points</b> not awarded to their quoted product of <b>M/s. Mactor</b> which is in top 20 companies in IMS ranking. All mandatory documents were attached but company declared</p>	<p>All original documents from bid were duly checked and found that no paging available hence, no marks given.  Marks of ISOs &amp; GD were given according to documents provided for all Pharmaceuticals manufacturers pointed out in complaint except following:  <b>For M/s. Reckitt Pharma:</b></p> <ul style="list-style-type: none"> <li>- Documents checked found that 07 marks awarded to Stanley is according to suitability certificate of European source while clarification needed from expert (expert opinion is needed).</li> <li>- Same case of DML for Reckitt. On other hand the winner M/s. Stanley Pharma the DML and product registration certificate is expired and found application duly received by DRAP.</li> <li>- The GMP certificate of M/s. Stanley Pharma accepted by the CPC technical expert committee having wording for tender participation in Pakistan but for same wording M/s. ICI &amp; M/s. Genome Pharma which were disqualified. CPC to give justification.</li> </ul> <p><b>M/s. ICI &amp; M/s. Genome:</b></p> <ul style="list-style-type: none"> <li>- CGMP (Current Goods Manufacturing practice) to get clarification from DRAP (disqualified due to specific wording for tender participation in Pakistan. The firm is disqualified by CPC expert committee while on other hand M/s. FDL declared as qualified in Tender. CPC to give justification.</li> </ul>

S.#	Name of Complainant's and details of Complaint.	CRC Findings /	Decisions
	<p>"non-responsive". All GDS, CoAs and calibration certificate were attached but marks were not given. In matrix-II, there is so much errors have been found as <b>API source</b> accreditation, immediate container and <b>IMS ranking</b> which need to be discussable on a large scale.</p> <p>7.They have also pointed out that item code MGM0644 Pemetrexed 100mg and MGM0645 Pemetrexed disodium 500mg was not included in the evaluation report although they have quoted both products manufactured by <b>M/S. Macter International</b>.</p>		
7	<p><b><u>NEXT PHARMACEUTICALS</u></b> They have submitted reservation for invitation of tenders on QCBS method and pointed out discrepancies in scoring methodology for consideration.</p>	The CRC observed that the tenders were invited by the CPC on QCBS method as allowed by the Sindh Cabinets in the year 2018-2019 and allowed for such amendments in rules in its meeting held on 22.07.2019. In view of Cabinet decision CRC unanimously rejected the grievances and uphold the decision of CPC.	
8	<p><b><u>AJM PHARMA</u></b> <b>MGM 0211&amp; 0213 ODEROX</b> M/s. <b>AJM Pharma</b> stated that they made bid for item No. 307 MGM0211 and Item No. 308 MGM0213 a new unknown company by the name of <b>M/s. Vimits Pharma</b>, competed in this tender with defarsirox namely Roxwin and qualified. Their eligibility last and current year is highly controversial and against SPPRA Rule. They pointed out following reservations: <b>Impurity in generic:</b> Generic should be free from impurity: a. Levels of 4 – Hydrazino Benzoic Acid (4-HBA). It has been observed that the generic (Deferasirox) used for major patients contain high levels of 4-HBA that results in high incidence of side effect. b. These genotoxic impurities can interact with DNA and produce Cytotoxic effect and damage DNA may lead or contribute to tumor development. c. Vascular aneurysm and sudden rupture to fatal outcome. <b>Market experience:</b> The generic lack the market experience as required in the evaluation criteria since they have being marketed in the recent past and non-available in any tertiary care hospital / teaching institute of Pakistan except <b>MSD Sindh</b> and also not available at open market as well as chain pharmacy. <b>FDA APPROVAL / ISO CERTIFICATION:</b> This generic that competed in the tender did not possess any FDA approval or ISO certification therefore, they are not eligible to qualify for the tender at all. They state that International Authority like Thelesimia International Federation in a press release in July 2015 stated following points for generic drugs: "The cheaper use of generic drugs is becoming a major tool for achieving accessibility and availability of drugs to patients across and between countries of the globe."</p>	CRC examined the complaints and unanimously decided that matter may be referred to Heamatology, DUHS and NICH, Karachi for expert opinion. It is also suggested that data to be collected from all Thalassaemia Centre Badin for use of such drugs.	



S.#	Name of Complainant's and details of Complaint.	CRC Findings / Decisions
	<p>"The use of cheaper drugs should, however, under no circumstances jeopardize their quality and effectiveness." Nothing is truly more expensive, in the end, than a treatment failure from an ineffective drug or from a drug that causes side and adverse, leading to poor adherence increase of morbidities and even fatalities" noted the President of TIF, Mr. Panos Englezos in one of his messages to patients and health professionals." They requested to discuss the sensitivity and severity of this issue in larger benefit of the patients.</p>	
9	<p><b><u>OTSUKA</u></b>  <b>TENDER-1 GROUP-D</b>  <b>IV FLUIDS / INFUSION.</b>  They have submitted reservation for tender No. 01 (Group-D). They submitted that they didn't get export certificate number, which is an omission they gave to exporting Afghanistan and Kenya and attached the documents in support. They further stated that their quoted products are lower in price than other parties, yet bid has been awarded to others just because of non-technical grounds which is an un-principled act of Govt. of Sindh. They requested to consider 5 marks of export certificate they didn't get appropriate marks.</p>	<p>CRC examined the export certificate which is of 20 years old issued from CCI (Chamber of Commerce and Industry) instead of DRAP.  As regard his claimed for export to Afghanistan and Kenya. The CPC to review it.</p>
10	<p><b><u>PARAMOUNT TRADERS</u></b>  <b>MGM-1 GROUP-A</b> 0064, 0145, 0146,  <b>MDP-</b> 0028, 0030, 0047, 0049, 0050, 0074, 0081, 0083, 0147  <b>MGM-B</b> 0253, 0300, 0301, 0317, 0325, 0461, 0573, 0622, 0623, 0829, 0070 &amp; 0662  They submitted that they are selling of M/s. <b>Bonson Pharma</b> in allover Pakistan they stated that M/s. <b>Bonsor Pharma</b> declared technically disqualified mentioned reason that it is not attested from FID, despite that almost all quoted products obtained highest combined evaluated score as well lowest in rates. They stated that the M/s. Bonson products are FID attested but another firm mentioned typographically in column. They requested to re-evaluate and give the point against said documents.</p>	<p>CRC Checked from the papers attested by FID and decided that the same may be considered by clarification from DRAP.</p>
11	<p><b><u>HASSAAN DISTRIBUTION</u></b>  <b>TENDER NO-1 GROUP-B</b>  MGM 0633 0299, 0213, 0229, 0496, 0497, 0743, 0464, 0079, 0279, 0600, 0601, 0745, 0584, 0754, 0756, 0573, 0577, 0575, 0576, 0298, 0623, 0300, 0301,  <b>TENDER-01 GROUP-A</b>  <b>MGM-0064</b> MDP-0141, 0142, 0045, 0051, 0052, 0027, 0028, 0030, 0084, 0085, 0086, 0047, 0049, 0050, 0725, 0726, 0727, 0728, 0736  They have submitted grievances for tender No. 01 (Group-A) and (Group-B). As per details given below:  <b>Tender-01 (Group-A):</b>  M/s. Genix Pharma = Technically qualified but score of current export certificate but awarded another firms</p>	<p>CRC examined the complaint and observed that marks are fair as checked from original record and bid evaluation report, hence, CRC rejected the complaint and unanimously decided to uphold the decision of CPC.</p>

S.#	Name of Complainant's and details of Complaint.	CRC Findings / Decisions
	<p>M/s. Shadani &amp; M/s. RTJ Enterprises received scores of export certificate for the same company i.e. M/s. Genix. M/s. Pharmeveo = said firm is technically qualified but due to GD certificate were not received declared Non-responsive. They cannot submit GD as a source of raw material is based on local purchase.</p> <p>M/s. Pacific Pharma = it is company leading company for tuberculosis medicines and always qualified in MSD tender but this year it got disqualified without any reason although this is single quoted company of such product. They have pointed out some products of M/s. Glitz Pharma secured highest combined evaluated score as well as lowest in rates but awarded to other company mentioned typographically in columns.</p> <p><b>Like:</b>  MGM0299 = Awarded to M/s. Indus Pharma instead of M/s. Geofman.  MGM0213 = Awarded to M/s. Wimitts instead of M/s. Glitz.  MGM0222 = Awarded to Martin Dow instead of M/s. Glitz.  MGM0496 = Awarded to M/s. Platinum Pharma instead of M/s. Glitz Pharma.  MGM0497 = Awarded to M/s. Platinum Pharma instead of M/s. Glitz Pharma.  MGM0743 = Awarded to M/s. Caraway Pharma instead of M/s. Glitz Pharma.</p> <p>They also pointed out that they have quoted some products of M/s. Mass Pharma and M/s. Novamed Pharma with declared disqualified from their side but mentioned qualified firm M/s. Hamza and M/s. Sky Pharma.</p> <p>They have also pointed out mistake in quoted rates of their approved products which was quoted by them @ Rs. 4.75 but wrongly mentioned Rs. 1.75.</p>	
12	<p><b><u>ZEAL PHARMACEUTICAL</u></b>  <b>TENDER-1 GROUP-A</b>  Inj. Meropenem 1 g  They have submitted grievances against Tender No.01 (A) and informed that CPC incorrectly evaluated their bidding documents for the products of M/s. Global Pharma quoted by them and pointed out following:</p> <ol style="list-style-type: none"> <li>1.The manufacturer uses Type-I container for the glass of its ampoules and vials and provided all supporting documents but CPC incorrectly evaluated it as Type-2.</li> <li>2.They have provided proper Table of contents, Index numbering and proper file binding and yet CPC deducted 03 points.</li> </ol> <p>So 05 points were incorrectly were incorrectly deducted because of which they could not win many products including two very major drugs Inj. Meropnem 1g and 500mg which were awarded to another company at high rate on difference of Rs. 130/- &amp; Rs. 50/- per vial respectively, come total loss of 77.00 million due to high rates.  They have requested to re-evaluate the same correctly.</p>	<p>CRC examined the complaint and while reviewing the original record observed that the complainant not paging their bid in tender document but Type-I marks of four for glass quality may be awarded instead of 2 marks.</p>




S.#	Name of Complainant's and details of Complaint.	CRC Findings / Decisions
13	<p><b><u>EASA BUSSINESS GROUP</u></b>  <b><u>TENDER-1 GROUP-B</u></b>  MGM -287 MDP-0096 &amp; 0097.  Tender No. 01 (Group-A):  They have informed that they have quoted following products of M/s. Pfizer Pakistan but mistakenly uploaded on line in imported items, instead of local manufacturer. They have submitted all documents of local manufacturer in hard copy but due to mistaken in online submission their single quoted product declares rejected:  1. MDP0096 Inj. Dalacin 300mg, Pfizer  2. MDP0097 Inj. Dalacin 600mg, Pfizer  Tender No. 01 (Group-B)  They submitted that they have queted Inj. Enterncept 50mg/ml of M/s. Wyeth Pakistan and provided all documents including "Product Profile" but the same declared "Disqualified" due to non-submission of "Product profile".  They stated that they are single quoted for above essential drugs and once again they can provide product profile again for said product.</p>	<p>Verified original tender documents and found that no product profile papers attached in bids hence, CRC decided to reject his complaint.</p>
14	<p><b><u>SAAD SALES SERVICES</u></b>  <b><u>TENDER-1 GROUP-B</u></b> MGM-0815  <b><u>TENDER-1 GROUP-D</u></b> MIV-0030  They have pointed out that their quoted item No. 430 &amp; MGM 0815 Inj. Streptokinase vial of 1.5 M.I.U. @ Rs. 5,019/- each but the same has been written as Rs. 50.19, due to typing error. They requested to make correction and issue award letter, accordingly.</p>	<p>CRC verified from original record on financial proposal of M/s. Saad Sales Services, who have offered the rate 5,019/- rectified from BER and may be read as 5,019 instead of 50.19.</p>
15	<p><b><u>B. BRAUN</u></b>  MIV 0030  They have pointed out that their quoted items No. MIV0030 Inj. Modified 4% fluid Gelatin 500ml @ Rs. 359.97 each but the same has been written as Rs 369.00 due to typing error. They requested to make correction and issue award letter, accordingly.</p>	<p>Checked and verified from original record of M/s. B.Braun. They have quoted Inj. Modified 4% gelafusion @ Rs. 359.97 on original financial proposal and may be read as 359.97 instead of 369.00.</p>
16	<p><b><u>SAGAR MEDICOS</u></b>  MGM 0489, 0763, 0764, 0033, 0056, 0069, 0077, 0131,, 0346, 0410, 0472, 0912, 0915 &amp; MDP 0170 &amp; 0012  Tender 01 (Group-A &amp; B)  They informed that they quoted the items on behalf of M/s. Zafa Pharma but due to unjustified scoring following grievances are submitted against above mentioned items:  - They have submitted documents related to ISO-14001 &amp; 18001 and provided web link for verification but 06 marks for both ISOs were not added in factory score, which change the total</p>	<p>CRC after scrutiny of original record observed that the complainant provided expired ISO's in their bids hence, marks were not awarded.  CRC decided to reject the complaint.</p>

*Agar*

*[Handwritten signature]*

S.#	Name of Complainant's and details of Complaint.	CRC Findings / Decisions
	<p>winning results besides their rates were very low than approved bidder. They have submitted the comparison of winning score and their score after adding of 06 marks.</p> <p>They requested to re-evaluate the same justifiably.</p>	
17	<p><b><u>M.I. ENTERPRISES</u></b>  <b>MGM 0302, 0369, 0619, 0662, 0681, 0681, 0741, 0743, 0745, 0148 0439 MDP 0045, 0052, 0054, 0057,0101, 0174,</b></p> <p>They have submitted item wise grievances against Tender No. 01(A) &amp; (B), which are as under:  Tender No. 01(A) &amp; Tender-01(B):</p> <ol style="list-style-type: none"> <li>1. They have pointed out discrepancies for allocation of marks to approved bidder and their quoted products individual with justification of each as per attached application.</li> <li>2. They have pointed out additional marks given to approved bidders in respect of ISOs, IMS Data, immediate container Type-I instead of Type-II &amp; API source etc., which are not justifiable. They have pointed out such discrepancies item wise in their application attached.</li> <li>3. One company M/s. Pharmasol approved in item No. MDP010, on giving marks of ISO-18001, ISO-14001 and 9001 but the same company quoted by them declared ISO-14001 and ISO-9001.</li> </ol> <p>Moreover, export certificate not available with item but 05 marks given for said bidder , but "0" mark given for items quoted by them.</p>	<p>CRC examined the original record and after scrutiny the record following decision were made:</p> <ul style="list-style-type: none"> <li>- For tablet Olanazipine 02 additional marks for Type-I will be added.</li> <li>- MGM068 Lotion permethrin 02 additional marks will be awarded.</li> <li>- For item MDP0101 API Source of competitor suspicious and the competitor financial soundness less than 200 million, therefore, CPC to review it.</li> </ul>
18	<p><b><u>AL MUSTAFA ENTERPRISES</u></b>  <b>TENDER-1 GROUP-A MDP 0003 &amp; 0175 MGM 0239</b>  <b>TENDER -1 GROUP-B MGM 0300, 0464, 0899, 0455, 0436 &amp; 0068,</b>  <b>TENDER -1 GROUP-G MGM 0022.</b></p> <p>They have submitted reservation on Tender No. 01 (A), (B) &amp; (G), which are as under:  Tender No. 01(A):</p> <p>They have submitted / pointed out discrepancies for allocation of marks on following items as per detail given below:</p> <p><b>1. Item Code MGM0300 Cap. Esomeprazole 20mg:</b></p> <ul style="list-style-type: none"> <li>• Award mfg. Shaigan Pharma, Brand Name Esso Rates 5.38/- Total score 81.4349. They have skipped 03 numbers for technical bid documents by bidder arrange as sequence.</li> <li>• Give them 02 marks for Valid calibration certificate for equipment in the factory divided into production=02 marks &amp; quality control=02 marks they submitted both documents and requesting for rechecking of files for getting 02.</li> <li>• Requesting for 05 marks for APIs/ raw source accredited by WHO, US FDA EMA MHRA TGA, PMDA, Swiss Medic or Health Canada or by other SRAs=7 &amp; other source=05 marks, they informed that they submitted APIs sources and eligible for 07 marks.</li> <li>• If the 07 marks will be added in total score they will</li> </ul>	<p>CRC examined the complaints and after verification of record decided that for Item No. MGM0899 &amp; MGM0455, two (02) additional marks will be awarded.</p>



S.#	Name of Complainant's and details of Complaint.	CRC Findings / Decisions
	<p>securing 86.00 &amp; will be entity for award.</p> <p><b>2. Item Code MGM0464, inj: Iron sucrose 100mg/5ml.</b></p> <ul style="list-style-type: none"> <li>• They informed that their three (3) numbers were skipped for "Technical bid documents by bidder arrange.</li> <li>• They got two (2) marks for clause "Certificate of the material used for the immediate container of the quoted items. As issued by the manufacturer for Type-II container=02 marks and Type-I container=04 marks even we are eligible for Four (4) marks. They also submitted required documents as Type-I container and informed that they eligible for Four (4) marks.</li> <li>• They got zero numbers against financial soundness. Basically Hudson pharma is a part of ismail group of company. They are more than Rs. 27 billion tax payer in FBR.</li> <li>• They requested for addition above requested total fifteen (15) numbers and will be stand on Total F+P=74+lowest 20=94.0000.</li> </ul> <p><b>3. Item Code MGM0899, inj: Vitamin D320000 (Cholecalciferol).</b></p> <ul style="list-style-type: none"> <li>• They informed that their three (3) numbers were skipped for "Technical bid documents by bidder arrange.</li> <li>• They got two (2) marks for clause "Certificate of the material used for the immediate container of the quoted items, as issued by the manufacturer for Type-II container = 02 marks &amp; Type-I = 04 marks even we are eligible for Four (4) marks".</li> <li>• They got zero marks against financial soundness. Basically Hudson pharma is part of ismail Group Company. They are more than Rs 27 billion tax payer per year in FBR.</li> <li>• They requested for addition above requested total fifteen (15) numbers so we will be stand on Total F+P=74+lowest 16.3134=90.3134 and eligible for award.</li> </ul> <p><b>1. Item Code MGM0455, INH: Ipratopium Bromide 250mcg.</b></p> <ul style="list-style-type: none"> <li>• They informed that their three (3) numbers skipped for "Technical bid documents by bidder arrange.</li> <li>• They got only two (2) numbers for clause "Certificate of the material used for the immediate container of quoted items as issued by the manufacturer for Type-II container = 02 marks, Type-I container = 04 marks. They submitted for type-2 documents and requested for four (4) marks and for eligible said item.</li> <li>• They got zero number against financial soundness. Basically Hudson pharma is part of ismail group of company. They are more than Rs 27 billion tax payers in FBR.</li> <li>• They requested for addition of total Seventeen (17) marks then will be stand on Total F+P=74+lowest 20=94.0000.</li> </ul> <p><b>5. Item Code MGM0436, inj: Diazepam 10mg/2ml.</b></p> <ul style="list-style-type: none"> <li>• MS Aries Pharma is responsive &amp; lowest amongst all bidders. Awarded mfg Martin Dow, Brand name: Inj Valium quoted rates 33.15/- Total score 79.0890 &amp; gauge them with low numbers.</li> <li>• Zero marks for "Technical bid documents submitted by bidder arrange as below sequence" marks even we have submitted all files with index &amp; annexure on the top of file, they informed that they are eligible.</li> <li>• Two marks (2) for "Validation calibration certificate for equipment in the factory divided into production = 02 marks &amp; quality control=02 marks. For getting the marks they submitted both documents.</li> </ul>	

*[Handwritten signatures]*



S.#	Name of Complainant's and details of Complaint.	CRC Findings / Decisions
	<ul style="list-style-type: none"> <li>• Zero marks for "Pakistani market as in the recent most data of IMS health for allocation of marks for share slabs. 01-25% share=01 mark, 26-50% share=02 marks, 51-75% share=03 marks, above 76% share=04 marks. They informed that they are eligible for one (01) mark according to Data of IMS health.</li> <li>• They requested for six (6) marks so our Total score will be 85.0000 and will be entity for award.</li> </ul> <p><b>6. <u>Item Code MGM0068, Tab: Ascorbic Acid 500mg.</u></b></p> <ul style="list-style-type: none"> <li>• MS Abbott Laboratories (Pakistan) Ltd is responsive in comparative Quoted Brand Name: Tab: Cecon, Quoted rates 2.67/- Total score 89.0300. They give them 16.0300 marks and informed that they are eligible for at least 18.0300 marks for Total score as well they skipped their our following clause numbers.</li> <li>• They got zero marks for "Technical bid documents submitted by bidder arrange as below sequence" marks. They informed that they submitted all files with index &amp; annexure on the top of the file and eligible for three marks.</li> <li>• They requested for addition of above mentioned requested marks then they will stand on Total score 94.0300 and will be board on number one position of award.</li> </ul> <p><b><u>Tender No.01 (Group-B)</u></b></p> <p><b>1. <u>Item Code MDP0003, Inj: Amikacin 500mg/2ml</u></b></p> <ul style="list-style-type: none"> <li>• They informed that their three (3) numbers were skipped for "Technical bid documents by bidder arrange.</li> <li>• They got zero number against financial soundness. Billion tax payer per year in FBR.</li> <li>• They requested for consideration as group of company as you give 10 marks for Aspin pharma.</li> <li>• They requested for addition their above requested total thirteen (13) marks then will be stand on Total score F+P=78 lowest 20=98.0000.</li> </ul> <p><b>2. <u>Item Code: MGM0239, Syp: Diloxanide furoate 250mg/10ml + Metronidazole 200mg/10ml.</u></b></p> <ul style="list-style-type: none"> <li>• Awarded this product to mfg Stanley pharma Peshawar, Brand Name: Zoli, Rates 55/- Total score 92.0000</li> <li>• Zero numbers for "Technical/Bid documents submitted by bidder</li> <li>• They got five(5) marks for "APIs/raw source accredited by WHO, US-FDA, EMA, MHRA, TGA, PMDA, Swiss Medic or Health Canada or by other SRAs=07 &amp; other source=05 marks, and also informed that submitted APIs source for SRAs &amp; eligible for seven (7) marks.</li> <li>• They requested for above seven (7) marks then total score will be 98.9166 &amp; will be eligible for award.</li> </ul> <p><b>3. <u>Item Code: MDP0175 Inj: Vanomycin 0.5gm &amp; MDP0174 Inj: Vanomycin 1gm.</u></b></p> <p>Abbott Vancomycin API source is FDA approved and it is being manufactured at high tech lyophilizer which is European source &amp; has the capability to freeze the product at a temperature as low as -40C.</p> <p>They informed that these unique benefits of Vacomycin Abbott provide superior efficacy &amp; better safety margin compared to competitor Vancomycin thus not only physician to control infection.</p> <p>Since this item is high clinical importance they requested to ask all the responsive bidders to provide details of lyophilization &amp; chromatographic process, lyophilizer standard in the best interest of patients.</p>	




S.#	Name of Complainant's and details of Complaint.	CRC Findings / Decisions
19	<p><b>SAMI PHARMACEUTICALS</b>  <b>TENDER NO-1 GROUP-B</b>  MDP0171 &amp; 0138  They have requested for correction of rates, as the same were inadvertently mentioned in report, which are as under:  Quoted rates    Inadvertent Rates     in Report  01). MDP 0171  5.50                  50.00/Cap.  In price format,  02). MDP0138  12.53                12.53  In financial Bid Form-4    22.84  They requested to correct the rates as per their financial bid as under:  1. MDP0171 TRANEXAMIC ACID  Rs. 5.50/Cap. Instead of 50.00/Cap.  2. MDP0138 TAB. LINEZOLID 600MG  Rs. 22.84/Tab. Instead of 12.53/Tab.</p>	<p>CRC examined the original record and found typing error in BER which should be rectified as Rs. 5.50 instead of Rs. 50/-.  In case of item No. MDP0138 the rate quoted by M/s. Sami Pharma which is Rs. 22.84 but in same proposal they also quoted the rate for same item is Rs. 12.53. The CPC to review the rate offered by the bidders.</p>
20	<p><b>A TO ZEE INTERNAIONAL</b>  <b>TENDER NO-1 GROUP-A</b>  MDP 0050, 0047, 0121, 0141, 0142, <b>GROUP-B</b>  <b>MGM 0416, 0112, 0805, 0016, 0018, 0095, 0605, 0606, 0854, 0516 &amp; 0517</b>  <b>GROUP-F</b>  MDP 0116, 0117, MGM 0136, 0137, 0262, 0263, 0634, 0941, 0251, 0457 &amp; 0458.  M/s. A to Zee submitted following grievances for consideration:  Rejection/Disqualification of M/s. ICI Pakistan in Tender No. 01(A) &amp; (B).  - They stated their quoted manufacturer M/s. ICI Pakistan declared as "Non-responsive" due to reasons that they have not provided mandatory documents.  - The reason is not correct as on 27.10.2020, when they called by evaluation committee for checking/verification of submitted documents, all the mandatory / relevant documents were available in the file. Evaluation Committee only informed that cGMP of ICI Pakistan needed to be verified from DRAP Peshawar due to sentence (Tenders participation in Pakistan) is printed on cGMP, and they will get verify from DRAP Peshawar,  - But on 29.10.2020, the CPC opened Financial Bids are declared M/s. ICU Pakistan as "Non-Responsive."  - After opening of financial bids, they have approached CPC time to time but they advised to lodge complaint / grievance after announcement of</p>	<p>The CRC examined the complaint and after verification of original record from the bid documents and decided that:</p> <ul style="list-style-type: none"> <li>- The cGMP certificate for M/s. FDL, ICI, Stanley and Genome as same wording but two firms M/s. FDL &amp; M/s. Stanley declared as qualified while then other two companies M/s. ICI &amp; M/s. Genome declared as disqualified. So CPC may justify.</li> <li>- <b>MGM0018:</b> Stability certificate found therefore 05 marks be awarded.</li> <li>- <b>MGM0850:</b> Single quoted orphanic basis may be awarded.</li> <li>- As Matrix-I is cleared as orphanic basis may be considered for 03 products for M/s. Atco. MGM0251, MGM0457 &amp; MGM0458.</li> <li>- The items No. MGM0850 and MGM0851 are single-quoted and can be considered as qualified.</li> </ul>

S.#	Name of Complainant's and details of Complaint.	CRC Findings / Decisions																																																
	<p>comparative statement.</p> <p>- M/s. ICI approached directly to DRAP Peshawar, who were issued verification letter to ICI confirm that said cGMP is verified from DRAP Peshawar.</p> <p>- They are also pointed out that another manufacturer i.e. FDL submitted cGMP with same sentences (Tender participation in Pakistan) printed on cGMP issued by DRAP Peshawar and same has been declared as "Responsive" and awarded items in the Tender. They provided copy of the same.</p> <p>- 2. Tender NO. 01 (Group-F): They have point out that the products having following Item code numbers won by M/s. Atco Laboratories on the basis of maximum marks &amp; best minimum prices but these products did not award to M/s. Atco due to duplicate entry:</p> <table border="1" data-bbox="212 824 651 1783"> <thead> <tr> <th>S. NO.</th> <th>ITEM</th> <th>AWARDED TO</th> <th>REMARKS</th> </tr> </thead> <tbody> <tr> <td>1.</td> <td>MDP0116 Gemcitabine 1gm</td> <td>Eli Lilly</td> <td>Duplicate entry</td> </tr> <tr> <td>2.</td> <td>MDP0117 Gemcitabine 200mg</td> <td>EliLilly</td> <td>Duplicate entry</td> </tr> <tr> <td>3.</td> <td>MGM0136 Carboplatinum 150mg/15ml</td> <td>Helix Pharma</td> <td>Duplicate entry</td> </tr> <tr> <td>4.</td> <td>MGM0137 Carboplatinum 450mg/45ml</td> <td>Helix Pharma</td> <td>Duplicate entry</td> </tr> <tr> <td>5.</td> <td>MGM0262 Doxorubicin 10mg/5ml</td> <td>Helix Pharma</td> <td>Duplicate entry</td> </tr> <tr> <td>6.</td> <td>MGM0263 Doxorubicin 50mg/25ml</td> <td>Pfizer</td> <td>Duplicate entry</td> </tr> <tr> <td>7.</td> <td>MGM0634 Paclitaxel 30mg</td> <td>Helix Pharma</td> <td>Duplicate entry</td> </tr> <tr> <td>8.</td> <td>MGM0941 Paclitaxel 100mg</td> <td>Graton Pharma</td> <td>Duplicate entry</td> </tr> <tr> <td>9.</td> <td>MGM0251 Docetaxel 80mg</td> <td>Not awarded</td> <td>Duplicate entry</td> </tr> <tr> <td>10.</td> <td>MGM0457 Irinotecan 100mg</td> <td>Not awarded</td> <td>Duplicate entry</td> </tr> <tr> <td>11.</td> <td>MGM0458 Irinotecan 40mg</td> <td>Not awarded</td> <td>Duplicate entry</td> </tr> </tbody> </table> <p>They have requested to rectify errors.</p>	S. NO.	ITEM	AWARDED TO	REMARKS	1.	MDP0116 Gemcitabine 1gm	Eli Lilly	Duplicate entry	2.	MDP0117 Gemcitabine 200mg	EliLilly	Duplicate entry	3.	MGM0136 Carboplatinum 150mg/15ml	Helix Pharma	Duplicate entry	4.	MGM0137 Carboplatinum 450mg/45ml	Helix Pharma	Duplicate entry	5.	MGM0262 Doxorubicin 10mg/5ml	Helix Pharma	Duplicate entry	6.	MGM0263 Doxorubicin 50mg/25ml	Pfizer	Duplicate entry	7.	MGM0634 Paclitaxel 30mg	Helix Pharma	Duplicate entry	8.	MGM0941 Paclitaxel 100mg	Graton Pharma	Duplicate entry	9.	MGM0251 Docetaxel 80mg	Not awarded	Duplicate entry	10.	MGM0457 Irinotecan 100mg	Not awarded	Duplicate entry	11.	MGM0458 Irinotecan 40mg	Not awarded	Duplicate entry	
S. NO.	ITEM	AWARDED TO	REMARKS																																															
1.	MDP0116 Gemcitabine 1gm	Eli Lilly	Duplicate entry																																															
2.	MDP0117 Gemcitabine 200mg	EliLilly	Duplicate entry																																															
3.	MGM0136 Carboplatinum 150mg/15ml	Helix Pharma	Duplicate entry																																															
4.	MGM0137 Carboplatinum 450mg/45ml	Helix Pharma	Duplicate entry																																															
5.	MGM0262 Doxorubicin 10mg/5ml	Helix Pharma	Duplicate entry																																															
6.	MGM0263 Doxorubicin 50mg/25ml	Pfizer	Duplicate entry																																															
7.	MGM0634 Paclitaxel 30mg	Helix Pharma	Duplicate entry																																															
8.	MGM0941 Paclitaxel 100mg	Graton Pharma	Duplicate entry																																															
9.	MGM0251 Docetaxel 80mg	Not awarded	Duplicate entry																																															
10.	MGM0457 Irinotecan 100mg	Not awarded	Duplicate entry																																															
11.	MGM0458 Irinotecan 40mg	Not awarded	Duplicate entry																																															

*Aga* 



S.#	Name of Complainant's and details of Complaint.	CRC Findings / Decisions
21	<p><b>MEDICAL CORPORATION</b>  <b>TENDER NO-1 GROUP-A</b>  MDP 0006, 0007, 0010, 0021, 0045, 0046, 0047, 0049, 0050, 0051, 0052, 0053, 005, 0056, 0057, 0058, 0059, 0060, 0061, 0079, 0080, 0081, 0082, 0083, 0128, 0130 &amp; 0132 <b>TENDER-1 GROUP-B</b>  MGM-0006, 0009, 0012, 0039, 0148, 0230, 0232, 0243, 0298, 0300 0301, 017,0318, 0323, 0419, 0535, 0536, 0537, 0554, 0555, 0556, 0573, 0575 0918, 0614, 0824, 0825, 0204, 0205,&amp; 0207  <b>TENDER NO-1 GROUP-C</b>  MBV 0027, 0028</p> <p>They have submitted general grievances that due to unjustified Technical scoring, the products of following were not declared successful.  Tender No. 01 (Group-A) = Products of M/s. Hamza Pharma.  Tender No. 01 (Group-B) = Products of M/s. Hamza Pharma.  Tender No. 01 (Group-B) = Products of M/s. Aster Life Science.  Tender No. 01 (Group-B) = Products of M/s. Hoffman Health.  Tender No. 01 (Group-C) = Products of M/s. Hoffman Health.</p>	<p>CRC checked original tender and found that claimed document not attached, so marks awarded fairly hence, complaint is rejected.</p>
22	<p><b>PARRAS ENTERPRISES</b>  <b>TENDER-1 GROUP-F</b>  MGM 0263, 0396, 0550,  <b>TENDER-1 GROUP-E</b>  HCV 0006, 0009  <b>TENDER-1 GROUP-A</b>  MDP 0052, 0053, 0055, 0059, 0061, 00176, 0028, 0085, 0086, 0147, 0064, 0611, 0001, 0002, 0006, 0010, 0050, 0051, 0056, 0057, 0058, 0060, 0084 &amp; 0181 B-0298, 0504, 0505, 0509, 0577, 0597, 0617, 0806, 0852, 0856, 0857, 0008, 0011, 0364, 0366, 0676, 0754, 0862, 0054, 0317, 0573, 0575, 0622, 0662, 0780, 0915, 0918, 0069, 0070, 0095, 0545 &amp; 0764</p> <p>They have submitted general grievances that due to unjustified Technical scoring, the products of following manufacturers were not declared successful.</p> <ol style="list-style-type: none"> <li>1. M/s. Helix Pharma = Tender 01 (Group=A, B, &amp; F)</li> <li>2. M/s. SJG Fazal Ellahi = Tender 01 (Group=A, B, &amp; E)</li> <li>3. M/s. Geofman Pharma = Tender 01 (Group=A, B)</li> <li>4. M/s. Amson Vaccines = Tender 01 (Group=A, B)</li> <li>5. M/s. Tabros Pharma = Tender 01 (Group=B)</li> </ol>	<p>CRC checked original tender and found that claimed document not attached, so marks awarded fairly hence, complaint is rejected.</p>

S.#	Name of Complainant's and details of Complaint.	CRC Findings / Decisions
23	<p><b><u>HUZAIFA ENTERPRISES</u></b>  <b>TENDER-1 GROUP-A MDP</b> 0028, 0037, 0043, 0044, 0045, 0046 0047, 0048m, 0049, 0050, 0051, 0052, 0053, 0055, 0056, 0057, 0058, 0059, 0060, 0061, 0067, 0069, 0074, 0081, 0083, 0108, 0128, 0130, 0132, 0148, 0150, 0064, 0142, 0145, 0146, 0336, 0560, 0176,0027, 0066, 0124, 0137, 0138 &amp; 0181 <b>TENDER-1 GROUP-B MDP 0153, MGM</b> 0005, 0069, 0070, 0107, 0109,0175, 0182, 0254, 0265, 0302, 0317, 0323, 0330, 0504, 0506, 0509, 0520, 0540, 0620, 0624, 0625, 09662, 0774, 0775, 0816, 0852, 0860, 0862, 0958, 0071, 0072, 0256, 0298, 0364, 0366, 0573, 0575, 0584, 0622, 0678, 0679,0171, 0173, 0006, 0300, 0301, 0331, 0419, 0464, 0574 &amp; 0623  They have submitted their grievances as under:  A) MBV 0004  MBV 0005  MBV 0026  Their Principal company, CSL Behring  B) MBV0015 ASVS  Product is manufactured</p>	<p>CRC checked original tender and found that claimed document not attached, so marks awarded fairly.  For M/s. Inventor Pharma stability studies report did not found in proper format.  Hence, complaint is rejected.</p>
24	<p><b><u>HAKIMSONS (IMPEX)</u></b>  <b>TENDER NO-1 GROUP-C</b>  <b>MBV</b> 0004, 0005, 0026, 0015, 0004, 0005, 0026  They have submitted general grievances that due to unjustified Technical scoring, the products of following manufacturers were not declared successful.  M/s. Inventor Pharma = Tender 01 (Group=A, B)  M/s. Fynk Vaccines = Tender 01 (Group=A, B)  M/s. Caraway Pharma = Tender 01 (Group=A, B)</p>	<p>While reviewing the complaint CRC required clarification in respect of ISO's certification of SRA countries as cGMP issued from said country fulfilling the requirement of ISO certification. CRC decided to take clarification from Chief Drug Inspector / Drug experts.</p>
25	<p><b><u>LAB LINK ENTERPRISES</u></b>  <b>TENDER NO-1 GROUP-E</b>  HCV 001, MGM 0208, HCV 0024  They have submitted grievances on Hepatitis Item No. HCV001, HCV004 &amp; MGM0208.  They stated that they quoting same medicines from couple of years and the drugs is well received by Senior Professors for the high quality of product the product has SVR Data head to head Trials, WHO approved.  - On uploading of Technical evaluation, it is observed that those who were changed the evaluation criteria to accommodate a company.  - Approved company did not imported any raw material in the last year but got highest points. They are purchasing their raw material from a Chinese company, who does not have any one of certification required.  - Free sale certificate of their API resources is</p>	<p>CRC examined the complaint and while reviewing the record observed that all papers gone through and found that complainant got SVR marks but lost due to high price.  As regards the objection / complaint for quality of product, it can be evaluated by CPC.</p>

*Agar*

*[Handwritten signature]*

S.#	Name of Complainant's and details of Complaint.	CRC Findings / Decisions										
	<p>another question mark. - Series of violation may cause this tender name a suspected procurement and the approved company failed to comply with clause WHO approved.</p>											
26	<p><b><u>KARACHI MEDICAL COPMANY</u></b>  <b>TENDER NO-1 GROUP-B</b>  MGM 0349, MGM 0072  <b>TENDER NO-1 GROUP-G</b>  MGM 0959.  <b>TENDER NO-1 GROUP-G</b>  MGM 0959.  They have lodged complaint on following items:  <b>01(B) MGM0349 = Inj. Fluphengine</b>  It is a single quoted item and has been declared as "Non-responsive"  It is used .....  <b>01(B) MGM0072 = Inj. Atracurium Besylate</b>  <b>10mg / ml (5m)</b>  They quoted said product of M/s. Surge Lab, and provide letter about availability of "Functional stability chamber" but no marks given. They requested to grant such marks &amp; re-consider the same.  <b>01(G) MGM0959 = Inj. Remdesivir</b>  They informed that they have quoted this injection below the price recently fixed / notified by DRAP vide SRO dated: 07.12.2020 (copy attached).  But they were declared Non-Responsive an account of short documents. They requested to review the same.</p>	<p>The certificate of stability chamber was not attested by FID and also found that GSP HVAC certificates which were also not attested but excess marks were granted to the complainant which are required to deducted as a general rule, and CPC to review it accordingly.  For item No. MGM0959, CRC found that SRO was issued after completion of tender process and decided that this item cannot be considered after issuance of said SRO.</p>										
27	<p><b><u>ALLMED LABORATORIES</u></b>  <b>TENDER NO-1 GROUP-B</b>  MGM 0232, 0624, 0609, 0825  M/s. Allmed Laboratories submitted their grievances for following items and invite attention towards some key points, which have been overlooked during scoring prices, which are as under:</p> <table border="1" data-bbox="219 1478 657 2047"> <thead> <tr> <th>Item details</th> <th>Hospital Name</th> </tr> </thead> <tbody> <tr> <td>MGM0232 Avenac Inj. Diclofenac Sodium 75mg</td> <td>1. File indexing numbers not given. 2. Marking is 4 but we awarded 2 numbers.</td> </tr> <tr> <td>MGM0624 Anomed Inj. Ondansertron 8mg</td> <td>1. File indexing numbers not given. 2. Marking is 4 but we awarded 2 numbers.</td> </tr> <tr> <td>MGM0609 Epinor Inj. Norepinephrine Acid Tartrate 2mg/ml (Non-Adrenaline)</td> <td>1. File indexing numbers not given. 2. This molecular is 1<sup>st</sup> registered Brand in Pakistan Since 2011, but in tender IMS number is not awarded.</td> </tr> <tr> <td>MGM0825 Tacogen Tacrolimus 1 mg</td> <td>1. File indexing numbers not given. 2. They are using Type-I immediate container which marking is 4 but awarded 2</td> </tr> </tbody> </table>	Item details	Hospital Name	MGM0232 Avenac Inj. Diclofenac Sodium 75mg	1. File indexing numbers not given. 2. Marking is 4 but we awarded 2 numbers.	MGM0624 Anomed Inj. Ondansertron 8mg	1. File indexing numbers not given. 2. Marking is 4 but we awarded 2 numbers.	MGM0609 Epinor Inj. Norepinephrine Acid Tartrate 2mg/ml (Non-Adrenaline)	1. File indexing numbers not given. 2. This molecular is 1 <sup>st</sup> registered Brand in Pakistan Since 2011, but in tender IMS number is not awarded.	MGM0825 Tacogen Tacrolimus 1 mg	1. File indexing numbers not given. 2. They are using Type-I immediate container which marking is 4 but awarded 2	<p>After examine the complaint and record of bid CRC decided that:  - For item No. MGM0232 &amp; MGM0609 two additional marks will be added for Type-I container.</p>
Item details	Hospital Name											
MGM0232 Avenac Inj. Diclofenac Sodium 75mg	1. File indexing numbers not given. 2. Marking is 4 but we awarded 2 numbers.											
MGM0624 Anomed Inj. Ondansertron 8mg	1. File indexing numbers not given. 2. Marking is 4 but we awarded 2 numbers.											
MGM0609 Epinor Inj. Norepinephrine Acid Tartrate 2mg/ml (Non-Adrenaline)	1. File indexing numbers not given. 2. This molecular is 1 <sup>st</sup> registered Brand in Pakistan Since 2011, but in tender IMS number is not awarded.											
MGM0825 Tacogen Tacrolimus 1 mg	1. File indexing numbers not given. 2. They are using Type-I immediate container which marking is 4 but awarded 2											

*Handwritten signature*

*Handwritten signature*



S.#	Name of Complainant's and details of Complaint.	CRC Findings /	Decisions
	<p>numbers. 3. This molecule is 1<sup>st</sup> registered Brand in Pakistan since 2013, but in tender IMS number is not awarded.</p> <p>They have requested to consider above points upon merit &amp; fair practice.</p>		
28	<p><b><u>R &amp; A ENTERPIRSES</u></b> <b>TENDER NO-1 GROUP-B</b> MGM 0382, 0384, 0386, 0387, 0788, 0958. 0597. They informed that they have quoted reputable manufacturer but due to unfair practice during the scoring, some of the documents were missing in their bid. They informed the forum that these documents were part of their bid. After said exercise, they signed the file verification but later they found that there were some other objection which were not brought in their knowledge. They have submitted that following documents, which were attached but not shown in scoring: <b><u>M/s. Pharm Evo</u></b> For item No. MGM0382 – Current export certificate. MGM0384 – Good storage practice. MGM0386 – Good declaration certificate. MGM0387 – API source. MGM0388 – Certificate of analysis MGM0358 - All above documents attached but marks were not given. <b><u>M/s. Sante Pvt. Ltd.</u></b> For item No. 0597 - Valid calibration certificate. - Pakistan market share. All above documents attached but markets were not.</p>	CRC checked original tender and found that marking is fair for GSP, GD & IMS data. Hence, complaint is rejected.	
29	<p><b><u>AL QADEER</u></b> <b>TENDER NO-1 GROUP-G</b> MGM 0959, 0180, 0253, 0300, 0302, 0461, 0573, 0584, 0622, 0623, 0860 &amp; 0489 - They have requested to re-check the score of following items: MGM-0180, MGM-0253, MGM0300, MGM-0302, MGM-0461, MGM-0573, MGM-0584, MGM-0622, MGM-0623, MGM-0860 &amp; MGM-0439. - They have also objected that item No. MGM-0959 Inj. Remdesiver was approved in favour of M/s. Hamza Enterprises (MTI MEDICAL) @ Rs. 8,700/-, which seem very higher as the DRAP Islamabad has been fixed maximum price of above item @ Rs. 5,680/- (copy enclosed). They stated that most of the manufacturer supplying such product @ Rs. 3700/- (DUHS) &amp; 2400/- (JPMC) which are more economical then approved rates. They requested to review the rates through re-tendering.</p>	CRC examined original bid document and found that no paging and claimed document not available in tender document. Hence, complaint is rejected.	

*Handwritten signature*

*Handwritten signature*

S.#	Name of Complainant's and details of Complaint.	CRC Findings / Decisions
30	<p><b><u>FINE LINE SALES &amp; SERVICES</u></b>  <b>TENDER NO-1 GROUP-A</b>  MDP 0147, 0081, 0083, 0128, 0130 &amp; 0611.  <b>TENDER NO-1 GROUP-B</b>  MGM 0039, 0301, 0412, 0413, 0630, 0820, 0069, 0070, 0076, 0077, 0241, 0242, 0292, 0826, 0827 &amp; 0493.  <b>Objection</b> for invitation of tender on QCBS method for the procurement of drugs / medicines 2020 - 21 dt.01-12-2020</p> <ul style="list-style-type: none"> <li>- They have submitted the grievances against Tender-01 (Group-A) and Tender-01 (Group-B) and stated that:</li> <li>- The marking criterion which was initially imposed for fair trial of every participating vendor and pharmaceuticals company has failed tribally as it was exploited as per convenience and marks were allotted on the basis of favoritism. Well known and deserving national and multinational companies were held illegible because the panel wasn't informed and learned enough to calculate marks fairly. They didn't follow any specified benchmark and scoring done was absolutely biased and preferential. Their quoted companies were not put to trial justify and marks were deducted inequitably. Their quoted companies were given less marks on API source where as other firms of equivalent status were given more marks even though their raw material is imported from within Asia as well. Furthermore, there is a distinct proof of manipulation in scoring of products.</li> <li>- The IMS score of our quoted items was essentially better than the ones chosen over them. The products which are not even available in the market are given full score and our readily available conventional items are affected with prejudice and bias against them.</li> <li>- They have attached annexure having detailed remarks and pinpointing of manipulation whenever evident and requested to address their grievances in a manner of fair trial and re-evaluation.</li> <li>- They have also submitted objection for invitation of Tender on QCBS method and scoring methodology which were only allowed by SPPRA for consultancy services.</li> </ul>	<p>CRC examined the complaint and original bid record and unanimously decided as under:</p> <ul style="list-style-type: none"> <li>- M/s. Highnoon Ltd. The documents for GSP, cGMP, HVAC &amp; stability found attested by the FID of Karachi but not considered by CPC evaluation committee with the remarks that these are not attested by concerned FID, which needs clarification from DRAP and then CPC to review it.</li> </ul>
31	<p><b><u>M.Y ENTERPRISES</u></b>  <b>TENDER NO-1</b>  MGM 0530, 0380, 0108, 0109, 0535, 0536 &amp; 0537.</p> <ul style="list-style-type: none"> <li>- They have submitted the grievances against Tender-01 (Group-A) and Tender-01 (Group-B) and stated that:</li> <li>- The marking criterion which was initially imposed for fair trial of every participating vendor and pharmaceuticals company has failed tribally as it was exploited as per convenience and marks were allotted on the basis of favoritism. Well known and deserving national</li> </ul>	<p>CRC while reviewing the original bid document observed that ISO certificates of M/s. Efroze did not verify and require clarification from expert.</p>

S.#	Name of Complainant's and details of Complaint.	CRC Findings /	Decisions
	<p>and multinational companies were held illegible because the panel wasn't informed and learned enough to calculate marks fairly. They didn't follow any specified benchmark and scoring done was absolutely biased and preferential. Their quoted companies were not put to trial justify and marks were deducted inequitably. Their quoted companies were given less marks on API source where as other firms of equivalent status were given more marks even though their raw material is imported from within Asia as well. Furthermore, there is a distinct proof of manipulation in scoring of products.</p> <ul style="list-style-type: none"> <li>- The IMS score of our quoted items was essentially better than the ones chosen over them. The products which are not even available in the market are given full score and our readily available conventional items are affected with prejudice and bias against them.</li> <li>- They have attached annexure having detailed remarks and pinpointing of manipulation whenever evident and requested to address their grievances in a manner of fail trial and re-evaluation.</li> <li>- They have also submitted objection for invitation of Tender on QCBS method and scoring methodology which were only allowed by SPPRA for consultancy services.</li> </ul>		
32	<p><b><u>Z.I. ENTERPRISES</u></b>  <b><u>TENDER NO-1 GROUP-A</u></b>  MDP 0047, 0049, 0050, 0108, 0336, 0128, 0130 &amp; 0131. GROUP-B MGM 0089, 0456, 0046, 0043, 0009, 0012, 0042, 0520, 0531, 0545, 0081, 0298, 0922 &amp; 0463.</p> <ul style="list-style-type: none"> <li>- They have submitted the grievances against Tender-01 (Group-A) and Tender-01 (Group-B) and stated that:</li> <li>- The marking criterion which was initially imposed for fair trial of every participating vendor and pharmaceuticals company has failed tribally as it was exploited as per convenience and marks were allotted on the basis of favoritism. Well known and deserving national and multinational companies were held illegible because the panel wasn't informed and learned enough to calculate marks fairly. They didn't follow any specified benchmark and scoring done was absolutely biased and preferential. Their quoted companies were not put to trial justify and marks were deducted inequitably.</li> </ul>	<p>CRC examined the complaint and following were decided:</p> <ul style="list-style-type: none"> <li>- The expert / pharmacist can decide it as Iron salt can be same as Iron. In case of financial soundness M/s. Don Valley has not provided Income Returns of FBR as others have provide for the year (2017, 2018 &amp; 2019) specified in bid documents. While competitors have provided the same must be verified by FBR then to decide.</li> <li>- 0043, 0009, 0012, 0042:</li> </ul> <p>In Tender papers the ISO certificates for M/s. GSK Karachi and manufacturing firm (M/s. Pharmatec) attached in original file but CPC expert committee rejected them that ISO certificates of GSK Jamshoro required instead of GSK Karachi and it be clear from expert.</p>	

*Aza*



S.#	Name of Complainant's and details of Complaint.	CRC Findings / Decisions
	<p>Their quoted companies were given less marks on API source where as other firms of equivalent status were given more marks even though their raw material is imported from within Asia as well. Furthermore, there is a distinct proof of manipulation in scoring of products.</p> <ul style="list-style-type: none"> <li>- The IMS score of our quoted items was essentially better than the ones chosen over them. The products which are not even available in the market are given full score and our readily available conventional items are affected with prejudice and bias against them.</li> <li>- They have attached annexure having detailed remarks and pinpointing of manipulation whenever evident and requested to address their grievances in a manner of fair trial and re-evaluation.</li> <li>- They have also submitted objection for invitation of Tender on QCBS method and scoring methodology which were only allowed by SPPRA for consultancy services.</li> </ul>	<ul style="list-style-type: none"> <li>- For M/s. Martin Dow ISO verification of NQA firm of certification firm may be verified for other competitors as the certification has issued their letter that due to technical fault in link the all ISO certificates issued by same firm will show the status withdrawn, then all competitors may be treated as per general policy / procedure and CPC to review it.</li> </ul>
33	<p><b>GSK</b> <b>TENDER NO-1 (A), MDP0090, 0093, 0094.</b></p> <ul style="list-style-type: none"> <li>- They have submitted the grievances against Tender-01 (Group-A) and Tender-01 (Group-B) and stated that:</li> <li>- The marking criterion which was initially imposed for fair trial of every participating vendor and pharmaceuticals company has failed tribally as it was exploited as per convenience and marks were allotted on the basis of favoritism. Well known and deserving national and multinational companies were held illegible because the panel wasn't informed and learned enough to calculate marks fairly. They didn't follow any specified benchmark and scoring done was absolutely biased and preferential. Their quoted companies were not put to trial justify and marks were deducted inequitably. Their quoted companies were given less marks on API source where as other firms of equivalent status were given more marks even though their raw material is imported from within Asia as well. Furthermore, there is a distinct proof of manipulation in scoring.</li> <li>- The IMS score of our quoted items was essentially better than the ones chosen over them. The products which are not even available in the market are given full score and our readily available conventional items are affected with prejudice and bias against them.</li> </ul>	<p>CRC examined the complaint and observed that Augmentin is mixture of Clavunic Acid and amoxicillin.</p> <p>Main component Clavunic Acid source of European, while the source of other API amoxicillin is from Pakistan – therefore, marks accorded as local source which shall be decided after to seek opinion from expert.</p>

S.#	Name of Complainant's and details of Complaint.	CRC Findings / Decisions	
	<p>- They have pointed out that unjustified scoring or winner in following items and informed that their API source is EU which score is 07 but comparative shows 05 score.</p> <p><b>Item Code MDP0090</b> Tab.Clavunic Acid + Amoxicillin 1 gr. (Augementin Tab 1000mg Dessiflex)</p> <p><b>Item Code MDP0093</b> Syp-Clavulanic Acid+Amoxicillin 156.25 mg/5ml (Augmentin syp. 156.25mg)</p> <p><b>Item Code MDP0094</b> Tab.Clavunic Acid + Amoxicillin 625 mg (Augmentin Tab 625mg Dessiflex)</p>		
34	<p><b><u>MEDIPAK LTD.</u></b> <b>TENDER NO-1 GROUP-D, IV FLUIDS .</b> They have submitted their grievance on the declaring them "Non-responsive" due to not securing 70% marks in Matrix-I. They have submitted the details of point, which should be awarded as the their given documents vide Annex-I &amp; Annex-II, following total marks: Factory score = 34 Product score = 25 or 27 They requested to take notice and resolve their grievances, accordingly.</p>	CRC examined original bid document and found that GMP is expired HVAC and GSP certificates are not attested by FID so marks were not awarded. Hence, CRC decided to reject the complaint.	
35	<p><b><u>S &amp; T CORPORATION</u></b> <b>TENDER NO-1 GROUP-A</b> <b>MDP 0053, 0055, 0059, 0060, 0061, 0084, 0230, 0723, 0724 &amp; 0952.</b> <b>Objection</b> for invitation of tender on QCBS method for the procurement of drugs / medicines 2020 - 21.</p> <ul style="list-style-type: none"> <li>- They have submitted the grievances against Tender-01 (Group-A) and Tender-01 (Group-B) and stated that:</li> <li>- The marking criterion which was initially imposed for fair trial of every participating vendor and pharmaceuticals company has failed tribally as it was exploited as per convenience and marks were allotted on the basis of favoritism. Well known and deserving national and multinational companies were held illegible because the panel wasn't informed and learned enough to calculate marks fairly. They didn't follow any specified benchmark and scoring done was absolutely biased and preferential. Their quoted companies were not put to trial justify and marks were deducted inequitably. Their quoted companies were given less marks on API source where as other firms of equivalent status were given more marks even though their raw material is imported from within Asia as well. Furthermore, there is a distinct proof of manipulation in scoring.</li> </ul>	While reviewing the original record, CRC decided that for item No. MDP0053, MDP0059, MDP0084: two additional marks for immediate container can be awarded.	

S.#	Name of Complainant's and details of Complaint.	CRC Findings /	Decisions
	<ul style="list-style-type: none"> <li>- The IMS score of our quoted items was essentially better than the ones chosen over them. The products which are not even available in the market are given full score and our readily available conventional items are affected with prejudice and bias against them.</li> <li>- They have attached annexure having detailed remarks and pinpointing of manipulation whenever evident and requested to address their grievances in a manner of fair trial.</li> </ul>		
36	<p><b>SHAMIM &amp; CO.</b>  <b>TENDER NO-1 GROUP-B MGM 0777, 0494.</b>  They have informed that their Principal company M/s. Getz Pharma informed that product "SEVOF" (Sevoflirane) liquid for inhalation 250ml is under evaluation and consideration by DRAP and not been allotted DR number till now.  They request for withdrawal of the quoted product "SEVOF (Sevoflurance) liquid from said tender.</p>	The CRC decided to refer to CPC for review it.	
37	<p><b>NOVARTIS PHRAMA PAK. GROUP-B MGM 0946, 0947 &amp; 0948</b>  They submitted that below brands has not been selected by the committee due to not securing 70% marks as per tender requirement they said that they provided those documents at the time of tender submission. Those document has been overlook at the time scrutiny. The details are as following:  <b>Point No. 01:</b>  Serial No. MGM0946, MGM0947 and MGM0948: Deferasirox 90 mg, 180mg, and 360mg Film coated Tablets Unavailability of IQVIA Market share date of Olegtiss 180mg, 90mg, 360mg.  Data in IQVIA was not available because Olesptiss (Deferasirox) is a newly launched brand of 2020. Please note that this is the only brand and strength available for thalassemia patients in Pakistan and Novartis is a sole proprietor of this product in Pakistan. They requested for ignorance this point because unavailability of IQVIA Data.  <b>Point No. 02:</b>  Missing COA and GMP  As mentioned on the website, COA and GMP was not enclosed. However, we enclosed all documents in tender.  <b>Point No. 03:</b>  No marks given for the free sale certificate. They enclosing certificate of a Pharmaceutical Product (COPP), which will fulfill the requirement of free sale certificate COPP is developed by Swissmedics which that this product is licensed and place in the market for use in exporting country.</p>	<p>CRC decided that for item No. 0946, 0947 &amp; 0948 :  The product quoted by M/s. Novartis Pharma is research and single quoted product can be considered as an orphanic drugs and can be considered for responsive.  The CPC to review it.</p>	
38	<p><b>MF TRADERS</b>  <b>GROUP-B MGM 0802 &amp; 0800</b>  They have submitted grievance, for following items of Tender No. 01 (Group-B).  1. MGM0802 Tab. Sodium Valporate 500mg  2. MGM0800 Syp. Sodium Valporate 120ml  They stated that M/s. Don Valley required 08 marks.</p>	To verify Tax return for financial year 2017, 2018 & 2019 from FBR and then to decide its financial soundness.	






S.#	Name of Complainant's and details of Complaint.	CRC Findings / Decisions
39	<p><b><u>Q. A TRADERS.</u></b>  <b>GROUP-B</b>  <b>MBV 0019, 0020 &amp; 0021.</b>  They have submitted grievance against following items:</p> <ol style="list-style-type: none"> <li>1. Item Code: MGM0046: Syp.Aminphyline B.P. 32mg + Ammonium Chloride B.P. 30mg + Menthol 0.98mg/120ml + Diphenhydramine B.P. 8m</li> <li>2. Item Code MBV0019: Inj.Erythropoitin 10000 Units.</li> <li>3. Item Code MBV0020: Inj.Erythropoitin 20000 Units.</li> <li>4. Item Code MBV0021: Inj.Erythropoitin 40000 Units.</li> </ol> <ol style="list-style-type: none"> <li>1. MBV0019: Inj.Erythropoitin 10000 Units of Macter International Ltd. has more then 72% market share in IMS Data for which they awarded 03 marks but instead they got/awarded only 01 mark.</li> <li>2. Calibration certificate of production and quality control department were complete, but awarded them 02 marks instead of 04 marks.</li> <li>3. Their technical/bid document submitted was properly arranged which contain 03 marks but not awarded them these marks.</li> </ol> <p>In item code MGM0046: Syp. Aminophyllin B.P. 32mg+Ammonium Chloride B.P. 30mg + Menthol 0.98mg/120ml + DiphenhydremineB.P. 8 m, 05 marks of Certificate of Analysis of API of the quoted item/s from the Principal manufacturer duly attested by the senior executive of the firm are missing in the technical evaluation and 01 mark of market share is less.</p>	<p>They have found Absent, hence, committee decided that complaint may set aside.</p>
40	<p><b><u>MULLER &amp; PHIPPS PAKISTAN</u></b>  <b>GROUP-B</b>  MGM 0071 They have submitted reservation on Item No. 18 MGM0071 Inj. Atracurium besylate 10mg / ml (3ml). They stated that Two firms participated as: M/s. Zafa Pharma.  M/s. Surge Laboratories.  Quoted injection same with 2.5ml strength instead of require specification 3ml.</p> <ol style="list-style-type: none"> <li>1. As per bidding documents required strength of the product was 3ml &amp; the same was quoted just by Brookes Pharma except of all bidder. According to requirement all companies should be declared non-responsive due to the strength difference or</li> <li>2. Quoted price should be considered a per demanded specification product.</li> <li>3. Financial soundness of M/s. Surge Lab. Is below the 600 million and according to evaluation criteria the allocated marks should be only 04 (four) while firm obtained 10 marks.</li> </ol> <p>They have requested to re-consider the same according to evaluation criteria.</p>	<p>CRC found that actual complain as per required specification M/s. Brooks Pharma is genuine as the winner product is of quantity 2.5ml which is against the specification, hence, this product will be awarded to M/s. Muller &amp; Phipps.</p>
41	<p><b><u>AL MUBASHIR ENTERPRISES</u></b>  Objection for invitation of tender on QCBS method for the procurement of drugs / medicines 2020 - 21 dt.01-12-2020.  They have objected on invitation of Tender as QCBS method and pointed out discriminatory</p>	<p>The CRC found from record that the authority letter of M/s. Roche Pharma Pakistan attached in original, hence, the CPC to review.</p>

S.#	Name of Complainant's and details of Complaint.	CRC Findings / Decisions								
	<p>Technical evaluation criteria and scoring methodology, which is allowed only for consultancy / service.</p> <p>Moreover, they have objected against the disqualification of their firm M/s. Roche Pakistan Ltd. Due to typing error / human error in authorization letter. They stated that they have submitted confirmation letter during evaluation process but evaluation panel refuse to accept the authorization letter. They pointed out that M/s. Roche Pakistan is only company who provide COVID-19 medicine.</p>									
42	<p><b>MEDIFLOW PHARMA</b>  <b>TENDER NO-1 GROUP-D</b>  <b>IV FLUIDS.</b></p> <p>They have submitted grievances against tender 01 Group-D) I.V. Fluids and pointed out erroneous calculation of scoring tabulation matrix.</p> <p>They stated that the marks given them are not justified as per their submitted documents, henceforth the reservation that there is a gaffe in the calculation of marks.</p> <p>1. The matrix allows marks on financial soundness. As FBR documents suggest that true financial soundness of each bidder. They notified that the stated bidder have been awarded wrong full marks in light of above extract from verified FBR tax returns report. According to accounting principles the term "Financial soundness" of a company is defined as <u>"the total value of assets less the total value of all liabilities gives your FINANCIAL SOUNDNESS net worth or equity of the firm"</u></p> <p>2. In product evaluation tabulation matrix they have not been awarded further marks on their APIs sources which are European origin and merit more marks then granted to them. The country of origin all their API/Raw Material sources sodium lactate, sodium chloride, calcium chloride, potassium chloride are from Europe which are EC certified and are of SRA countries list provided by WHO. They had enclosed relevant Good declaration documents and EC certificates but they were given 5 marks instead of 7 marks which shows not correct evaluation.</p>	<p>The CRC examined the complaint and found that for product Code 0034, 0035 of 500ml and 1000ml which is combination of electrolytes. Out of 03 electrolytes 02 are SRA accredited source, while 01 source is from China. On majority basis CRC approve the request for addition of two additional marks for API source.</p>								
43	<p><b>SKY PHARMA</b>  <b>TENDER NO-1 (A) MDP0082, MDP0083</b></p> <p>They informed that M/s. Sky Pharma Hyderabad is authorized distributor of M/s. Novamed Pharmaceuticals (Pvt) Ltd. and submitted their grievances against following quoted items:</p> <table border="1" data-bbox="243 1836 893 2060"> <thead> <tr> <th>Item Code</th> <th>Name of Product</th> <th>Name of Manuf.</th> <th>Total Score</th> </tr> </thead> <tbody> <tr> <td>MDP0082</td> <td>Susp: Ciprofloxacin 250mg / 5ml</td> <td>M/s. Novamed Pharma. (Pvt) Ltd.</td> <td>85.408</td> </tr> </tbody> </table>	Item Code	Name of Product	Name of Manuf.	Total Score	MDP0082	Susp: Ciprofloxacin 250mg / 5ml	M/s. Novamed Pharma. (Pvt) Ltd.	85.408	<p>After examination of complaint and verification of original record CRC found that:</p> <p>For product No. 0082 awarded to M/s. Sami, on verification the papers mentioning the website of Znejang Quobang as US (FDA) approved source of raw material considered the accreditation of European / US FDA / SRA countries for API sources considered in majority of cases which is not justifiable as the API source for individual generic of specified medicine can be</p>
Item Code	Name of Product	Name of Manuf.	Total Score							
MDP0082	Susp: Ciprofloxacin 250mg / 5ml	M/s. Novamed Pharma. (Pvt) Ltd.	85.408							


S.#	Name of Complainant's and details of Complaint.				CRC Findings / Decisions															
	MDP0083	Tab: Ciprofloxacin 500mg	M/s. Novamed Pharma.	88	<p>considered instead of whole the company which the technical expert committee has overlooked, so expert opinion be sought to decide.</p> <p><b>Sky Pharma:</b> For item No, MDP0083, tablet Ciproflocin 500mg product is awarded to M/s. Stanley Pharma for which European suitability certificate is attached in the original file (there is difference between suitability and accreditation), for which clarification is required from expert then to decide.</p> <p>They informed that they have submitted all the required documents included API Source of M/s. PharmGin and got 05 marks. Moreover, raw material manufactured at local basis (Pakistan) is being used by the National as well as multinational manufacturers including GSK, Barrett and others, they were allocated 05 marks but contrary to this, the 07 marks.</p> <p>They plea that the marks allocated to M/s. Amros, M/s. SAMI, M/s. Stanley &amp; M/s. Reign Pharma (their competitors) allocated 07 marks considering API Sources accredited by WHO, US, FDA, EMA, MHRA, TGA &amp; SRA countries which are unjustified and favoritism was made in favor of one manufacturer who otherwise will not win the said products if they don't got the marks are given below:</p> <table border="1" data-bbox="224 913 711 1234"> <thead> <tr> <th>Item Code</th> <th>Name of Product</th> <th>Name of Manuf.</th> <th>Total Score</th> <th>After correction total shall be</th> </tr> </thead> <tbody> <tr> <td>MDP0082</td> <td>Susp: Ciprofloxacin 250mg / 5ml</td> <td>M/s. SAMI Pharma. (Pvt) Ltd.</td> <td>87.1522</td> <td>85.1522</td> </tr> <tr> <td>MDP0083</td> <td>Tab: Ciprofloxacin 500mg</td> <td>M/s. SAMI Pharma. (Pvt) Ltd.</td> <td>89.5890</td> <td>87.5890</td> </tr> </tbody> </table> <p>They are requested for consideration and correction in BER for justice.</p>	Item Code	Name of Product	Name of Manuf.	Total Score	After correction total shall be	MDP0082	Susp: Ciprofloxacin 250mg / 5ml	M/s. SAMI Pharma. (Pvt) Ltd.	87.1522	85.1522	MDP0083	Tab: Ciprofloxacin 500mg	M/s. SAMI Pharma. (Pvt) Ltd.	89.5890	87.5890
Item Code	Name of Product	Name of Manuf.	Total Score	After correction total shall be																
MDP0082	Susp: Ciprofloxacin 250mg / 5ml	M/s. SAMI Pharma. (Pvt) Ltd.	87.1522	85.1522																
MDP0083	Tab: Ciprofloxacin 500mg	M/s. SAMI Pharma. (Pvt) Ltd.	89.5890	87.5890																
44	<p><b><u>SANOFI-AVENTIS PAKISTAN LTD.</u></b> <b>TENDER NO-1</b> <b>(GROUP-B)</b> <b>MGM0648, MGM0649</b></p> <p>They stated that the M/s. Sanofi's Brand items MGM0648 Avil Syrup 60ML Bottle and MGM0649 25mg Tablets, were marked as "Non-responsive", which are the single quoted item within the category, they are requested for reconsideration of Avil Syrup and Tablets for the benefit of patients.</p>				<p>CRC unanimously decided that for item Avil tablet and syrup 60 ml are single quoted, hence CPC to review it.</p>															
45	<p><b><u>NATIONAL AGENCIES</u></b> <b>TENDER NO-1</b> <b>(GROUP-A)</b> <b>MGM0949</b></p> <p>They informed that their quoted item MGM0949 Inj. Cefoperazone 1.5 Sulbactam was disqualified on technical basis. They requested for reconsideration of their technical documents.</p>				<p>After examination of complaints CRC found that M/s. Shamim &amp; Co. has withdrawn for supply of injection Sevoflorane. Both items Sevoflorance and Isoflorance are now orphan drugs and due to shortage in open market the said drugs are essential for Anaesthesia in the O.T's of the hospital, so CPC to review it.</p>															





S.#	Name of Complainant's and details of Complaint.	CRC Findings / Decisions
46	<p><b>POPULAR INTERNATIONAL TENDER NO-1 (GROUP-C) MBV0012</b></p> <p>They objected for technical grading of their quoted product and requested for re-evaluation and correct their quoted product score. They furnished details grievances as under:</p> <p><b>Item No. MBV0012 (Inj. Anti Rho (D) immune</b></p> <p>They got one mark in said item against valid proof of export by the principal manufacturer to US/Europe/SRA countries. While manufacturer Kedrin SPA Italy is located in Italy, Europe and the quoted product is EU/MHRA approved and exported all over the world including USA, Europe and SRA countries.</p> <p>Further, they got zero mark against stability studies of quoted item, while stability studies of IMMUNORHO is already attached in tender.</p> <p>On the basis of above grievances and documented evidence they have requested for acceptance of their grievances against above item for correction in grading and to award them.</p>	<p>CRC verified original record and observed that the stability study was not found as per prescribed specifications. Hence, marks cannot be awarded and the complaint is rejected.</p>

**Dr. Ali Sheer Khaskheli**  
Asstt. Professor of Surgery, SMBBMC  
Lyari, Karachi.

Representative of Accountant General  
Sindh, Karachi not attended the  
meeting.

  
**Dr. Sikander Qureshi**  
Head and Dean Medicine & Allied,  
SMBBMC Lyari, Karachi.

  
**Professor Dr. Azra Saleem,**  
Professor of Pharmacology, SMBBMC  
Lyari, Karachi.

  
**Dr. Kazim Hussain Jatoi**  
Secretary to Government of Sindh,  
Health Department.